This is not the most recent version of the article. View current version (9 MAY 2015)

Intervention Review

You have free access to this content

Antifibrinolytic drugs for acute traumatic injury

  1. Ian Roberts1,*,
  2. Haleema Shakur2,
  3. Katharine Ker1,
  4. Tim Coats3,
  5. on behalf of the CRASH-2 Trial collaborators2

Editorial Group: Cochrane Injuries Group

Published Online: 12 DEC 2012

Assessed as up-to-date: 14 JUL 2010

DOI: 10.1002/14651858.CD004896.pub3


How to Cite

Roberts I, Shakur H, Ker K, Coats T, on behalf of the CRASH-2 Trial collaborators. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database of Systematic Reviews 2012, Issue 12. Art. No.: CD004896. DOI: 10.1002/14651858.CD004896.pub3.

Author Information

  1. 1

    London School of Hygiene & Tropical Medicine, Cochrane Injuries Group, London, UK

  2. 2

    London School of Hygiene & Tropical Medicine, Clinical Trials Unit, London, UK

  3. 3

    Leicester Royal Infirmary, Department of Emergency Medicine, Leicester, UK

*Ian Roberts, Cochrane Injuries Group, London School of Hygiene & Tropical Medicine, North Courtyard, Keppel Street, London, WC1E 7HT, UK. Ian.Roberts@Lshtm.ac.uk.

Publication History

  1. Publication Status: New search for studies and content updated (no change to conclusions)
  2. Published Online: 12 DEC 2012

SEARCH

This is not the most recent version of the article. View current version (09 MAY 2015)

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
Auer 1979 {published data only}
  • Auer LM, Marth E, Heppner F, Holasek A. Proteolytic enzyme activity in patients with severe head injury and the effect of a proteinase inhibitor. Acta Neurochirurgica 1979;49(3-4):207-17.
CRASH-2 2010 {published data only}
  • CRASH-2 trial collaborators, Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011;377(9771):1096-101.
  • CRASH-2 trial collaborators, Shakur H, Roberts I, Bautista R, Caballero J, Coats T, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010;376:23-32.
McMichan 1982 {published data only}
  • McMichan JC, Rosengarten DS, McNeur JC, Philipp E. Posttraumatic lung syndrome. Definition, diagnosis, and therapy [Das Posttraumatische Lungen-Syndrom Defintion, Diagnose und Therapie]. Med Welt 1976;76(48):2331-9.
  • McMichan JC, Rosengarten DS, McNeur JC, Philipp E. Pulmonary failure after major trauma and shock. Intensive Care Medicine 1977;3:Abstract no. 37.
  • McMichan JC, Rosengarten DS, Philipp E. Prophylaxis of post-traumatic pulmonary insufficiency by protease-inhibitor therapy with aprotinin: a clinical study. Circulatory Shock 1982;9(2):107-16.
  • Rosengarten DS, McMichan JC, McNeur JC, Philipp E. Platelet and pulmonary insufficiency after bony trauma. Intensive Care Medicine 1977;3:Abstract no. 327.
  • Rosengarten DS, McMichan JC, Philipp E. The effect of prophylactic proteinase inhibitor therapy on post-traumatic pulmonary insufficiency and platelet counts. Advances in Experimental Medicine and Biology 1979;120B:349-60.
Yutthakasemsunt 2010 {published data only}
  • Yutthakasemsunt S, Kittiwattanagul W, Piyavechvirat P, Thinkhamrop B, Phuenpathom N, Lumbiganon P. Tranexamic Acid for preventing progressive intracranial hemorrhage in adults with traumatic brain injury; a preliminary report. National Neurotrauma Symposium. 14-17 July 2010.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
Gierhake 1971 {published data only}
  • Gierhake FW, Grabow L, Spitzer G, Muller C, Braun R, Hessler C, Orth HD, Skibbe G, Zimmerman K. Protease inhibitors and wound healing. Results of a double blind study. Der Chirurg 1979;42(8):360-3.
Husted 2003 {published data only}
  • Husted H, Blond L, Sonne Holm S, Holm G, Jacobsen TW, Gebuhr P. Tranexamic acid reduces blood loss and blood transfusions in primary hip arthroplasty: a prospective randomized double blind study in 40 patients. Acta Orthopaedica Scandinavica 2003;74(6):665-9.
Klobow 1977a {published data only}
  • Klobow H, Barthels M, Oestern HJ, Sturm J, Wannske M, Schaps D. Early changes of the coagulation system in multiple injuries and their modification with heparin and Trasyolol. Chirurgisches forum fur experimentelle und klinishe forschung 1977;April:119-23.
Klobow 1977b {published data only}
  • Klobow H, Barthels M, Oestern HJ, Sturm J, Trentz O, Wannske M. Early changes in the coagulation and fibrinolytic system in patients receiving heparin or trasylol after massive trauma. Intensive Care Medicine 1977;3:Abstract no 324.
Kuiian 1999 {published data only}
  • Kuiian SM, Pogosov VS, Kokliaeva NV, Tiukov VL, Riazanov VB, Gur'ianov VA, Akopian RG, Daikhes N, Davudov KhSh, Nazhmudinov I. The use of tranexamic acid as an anesthetic component in ENT surgeries in patients with high surgical-anesthetic risk and in hemorrhagic shock intensive therapy. Vestnik Otorinolaringologii 1999;1:47-51.
Loew 1970 {published data only}
  • Loew D. Pathophysiologic importance of kinins in traumatic shock. Langenbecks Archiv Fur Chirurgie 1970;327:1042-6.
Nissen 1989 {published data only}
  • Nissen R, Loeschke S, Peters A. Pharmacological treatment of post-traumatic oedema to allow early functional exercise. Langenbecks Archiv fur Chirurgie 1989;Supplement II:475-8.
Schneider 1976 {published data only}

References to ongoing studies

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
CRASH-3 {published data only}
  • Dewan Y, Komolafe EO, Mejía-Mantilla JH, Perel P, Roberts I, Shakur H, on behalf CRASH-3 Collaborators. CRASH-3 - tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. Trials 2012;13:87.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to ongoing studies
  4. Additional references
BTF 2000
  • The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care. Hypotension. Journal of Neurotrauma 2000;17(6-7):591-5.
CRASH-2 2011
  • CRASH-2 collaborators, Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, et al. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011;377(9771):1096-101.
Henry 2011
Heymann 1992
Higgins 2008
  • Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0. The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2008.
Kiwanuka 2004
  • Kiwanuka N, Gray RH, Serwadda D, et al. The incidence of HIV-1 associated with injections and transfusions in a prospective cohort, Raki, Uganda. AIDS 2004;18:343-3.
Lawson 2004
Murray 1996
  • Murray CJL, Lopez AD. Global health statistics: a compendium of incidence, prevalence and mortality estimates for over 200 conditions. Harvard School of Public Health, 1996.
Sauaia 1995